|
|
 |
 |
|
|
|
|
|
Approved in 2003, FUZEON® (enfuvirtide) is the first in a class of anti-HIV drugs called fusion inhibitors. Its “mechanism of action” (or the way it works) is completely different from existing anti-HIV drugs. Instead of working on the inside of T cells (CD4) to stop virus replication, FUZEON works on the outside where it can block entry (“fusion”) to the cell. This unique function gives fusion inhibitors the potential to treat resistant strains of HIV. Additionally, fusion inhibitors are considered less likely to cause unwanted side effects and interfere with other drugs in an anti-viral regimen.
The latest HIV treatment guidelines, issued by the US Department of Health and Human Services, currently support the use of FUZEON in combination with other anti-viral drugs to help treatment-experienced patients achieve undetectable viral loads — the ultimate goal of anti-HIV therapy. For more information about HIV treatment options and standards of care, please see our Resources section.
For more information about FUZEON, please visit www.Fuzeon.com.
|
|
|
|
|
|
|
|
|
|
|